Seroreactivity to the C6 Peptide in Borrelia miyamotoi Infections Occurring in the Northeastern United States | Zendy

Phillip J Molloy | Zendy; Karen E. Weeks | Zendy; Brittany P. Todd | Zendy; Gary P. Wormser | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Seroreactivity to the C6 Peptide in Borrelia miyamotoi Infections Occurring in the Northeastern United States

Author(s) -

Phillip J Molloy,

Karen E. Weeks,

Brittany P. Todd,

Gary P. Wormser

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix1023

Subject(s) - borrelia burgdorferi , medicine , lyme disease , serology , virology , borrelia , antibody , tick borne disease , immunology , tick

There are no US Food and Drug Administration (FDA)-approved diagnostic tests for Borrelia miyamotoi infection, an emerging tick-borne illness in the United States. The purpose of this study was to evaluate whether the FDA-approved C6 peptide enzyme-linked immunosorbent assay (ELISA) currently used to diagnose Lyme disease may potentially serve as a diagnostic test for B. miyamotoi infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research